To verify the superiority of pemafibrate over placebo and the non-inferiority of pemafibrate to the maximum dose of fenofibrate for determining the percent change in fasting serum triglyceride (TG) levels and to investigate safety by assessing the incidence of adverse events (AEs) and adverse drug reactions (ADRs). Methods: This phase , placebo/active drug-controlled, randomized, double-blind, parallel group comparison study enrolled patients with high TG and low high-density lipoprotein cholesterol levels. Patients were randomly assigned to receive placebo; pemafibrate 0.1 mg/day, 0.2 mg/day, or 0.4 mg/ day; or fenofibrate 100 mg/day or 200 mg/day for 12 weeks. Results: Among 526 randomized patients, 489 completed the study, with drop-out rates of 0%, 6.7%, 5.5%, 5.9%, 8.2%, and 10.7% in the placebo; pemafibrate 0.1 mg/day, 0.2 mg/day, and 0.4 mg/day; and fenofibrate 100 mg/day and 200 mg/day groups. The study showed the non-inferiority of pemafibrate 0.4 mg/day and 0.2 mg/day to fenofibrate 200 mg/day as well the non-inferiority and superiority of all pemafibrate doses to fenofibrate 100 mg/day for reducing TG levels. No dose-dependent increase in the incidence of AEs or ADRs was observed among the pemafibrate dose groups. The incidence of AEs and ADRs for all pemafibrate doses was similar to that for placebo and fenofibrate 100 mg/day and significantly lower than that for fenofibrate 200 mg/day (P 0.05).
Introduction
Reduction in low-density lipoprotein cholesterol (LDL-C) levels is a clinical priority for preventing cardiovascular disease. Even when LDL-C levels are reduced by drug therapy, the residual risk of cardiovascular disease still persists 1) . Although further reduction
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postprandial hypertriglyceridemia is related to the accumulation of TG-rich lipoproteins and their remnants, which have atherogenic effects 22) . Available preclinical and clinical data on pemafibrate suggest that this new drug, with its favorable benefit -risk balance, is more effective than conventional PPAR agonists. The current study was designed to further evaluate the effects of pemafibrate on TG levels in patients with high TG and low HDL-C levels. In particular, this trial compared the efficacy and safety of pemafibrate to the maximum dose of fenofibrate (200 mg/day).
Aim
The objectives of this phase study were to verify 1) the superiority of three doses of pemafibrate over placebo and 2) the non-inferiority of pemafibrate to the maximum dose of fenofibrate (200 mg/day) for reducing TG levels. The incidence of AEs and adverse drug reactions (ADRs) was investigated as the primary safety endpoint.
Methods

Trial Design
This phase , placebo/active drug-controlled, randomized, double-blind, parallel group comparison study was conducted in Japan in accordance with the Declaration of Helsinki and in compliance with the study protocol and Good Clinical Practice. Ethical approval was obtained from the Institutional Review Board at each trial center.
Patients
Patients with dyslipidemia, high TG levels, and low HDL-C levels were enrolled. All patients provided written informed consent before participation. After providing written consent to participate, they underwent laboratory testing twice during the screening period (within 8 weeks) to determine eligibility. Men or postmenopausal women age 20 to 74 years who had received dietary and exercise counseling for 12 weeks were eligible if two consecutive tests showed a serum TG level of 200 mg/dL and serum HDL-C level of 50 mg/dL for men and 55 mg/dL for women.
Patients with serum TG level of 1000 mg/dL were excluded, along with patients requiring other lipid-lowering medications during the trial; patients with type 1 diabetes, poorly controlled type 2 diabetes (HbA1c ≥ 8.4%), poorly controlled thyroid disease, poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg), renal dysfunction (serum creatinine level ≥ 1.5 mg/ in LDL-C levels may help decrease this residual risk 2) , growing evidence suggests that the pharmaceutical management of other lipid abnormalities also have clinical benefits. One condition for which such management can be applied is atherogenic dyslipidemia, which is characterized by high levels of triglyceride (TG)-rich lipoproteins that are commonly accompanied by low levels of high-density lipoprotein cholesterol (HDL-C) 3) . Patients with this type of dyslipidemia often have comorbidities that make them highly vulnerable to cardiovascular events, and effective therapeutic strategies must manage TG and HDL-C levels in addition to LDL-C levels 3, 4) . Fibrates, which activate peroxisome proliferatoractivated receptor alpha (PPAR ), can improve TG and HDL-C levels 5) . Fenofibrate, in particular, has been commonly used worldwide for this purpose. Clinical trials of fenofibrate and other fibrates have shown that TG levels decreased by about 25% to 50% and that HDL-C levels increased by 5% to 20% [6] [7] [8] , and some data suggest that fibrates can reduce the risk of cardiovascular events 8, 9) . For fenofibrate, the greatest risk reduction occurs in patients who have high TG ( 200 mg/dL) and low HDL-C ( 35 mg/dL) levels at the start of treatment 8, 10, 11) . However, fibrates, including fenofibrate, have been associated with increased risk of liver damage 12) and increased levels of serum creatinine, which is an indicator of kidney damage 13) . Most fibrates are excreted through the kidneys, and excretion is reduced in patients with compromised kidney function 8, 13) . According to the National Kidney Foundation, fenofibrate and several other fibrates are contraindicated in patients with abnormal kidney function test results 13, 14) . Fibrates can also affect the liver drug-metabolizing enzyme activity and therefore interact with other drugs such as gemfibrozil and statins 8, 15) . Pemafibrate (K-877) is a novel selective PPAR modulator (SPPARM ) with higher potency and selectivity for PPAR activation than fenofibrate 3, 16, 17) . Pemafibrate was identified from several candidate compounds with excellent potency and selectivity for PPAR as exerting more TG-reducing and HDL-C-increasing effects, but fewer adverse effects of increasing liver weight, than fenofibrate in animal studies 18) . Phase and studies have also shown promising safety and efficacy results 19, 20) . Pemafibrate was well tolerated, with no notable adverse effects on liver or renal function 3, 19, 20) . The incidence of liver-and kidney-related adverse events (AEs) was less in the pemafibrate groups than in the fenofibrate groups in these trials 19) . In addition, it has been reported that pemafibrate attenuated postprandial hypertriglyceridemia in laboratory animals (mice) 21) . A recent study has suggested that lysis at the two screening visits and at weeks 0, 4, 8, 10, and 12 of treatment. Mean baseline values were obtained using the results from two screening tests and measurements at week 0 for fasting serum TG, HDL-C (direct method), total cholesterol (TC), LDL-C (direct method), and non-HDL-C (direct method). Other parameters used measurements at treatment week 0 as baseline.
Randomization and Blinding
Randomization was performed by a third party responsible for allocation. Patient allocation was performed by the Patient Registration Center based on the provisional/final registration information and test results, and the trial drugs were prescribed according to the drug numbers indicated by the Patient Registration Center. Double blinding was implemented as follows: the person responsible for drug allocation prepared a key code and stored it until the key was opened. The key was opened after database locking.
Endpoints
The primary efficacy endpoint was the percent change in fasting serum TG levels from baseline to week 8, 10, and 12 after the start of treatment. The secondary efficacy endpoints were changes and percent changes in other parameters from baseline to the end of treatment, including HDL-C, TC, LDL-C, non-HDL-C, very-low-density lipoprotein cholesterol (VLDL-C), remnant lipoprotein cholesterol (RemL-C), apolipoprotein, glucose, and insulin levels and the homeostadL), or gallbladder disease or history of gallstones; patients with elevated liver enzyme levels (twice the upper limit of the normal range [ULN]), low hemoglobin levels (below 12 g/dL for men and 11 g/dL for women), or low fibrinogen levels (below the lower limit of the normal range [LLN] ); patients with a recent history of myocardial infarction (within 3 months prior to consent) or heart failure; or those with a malignant tumor.
Study Drug Administration
Eligible patients were randomly assigned to one of six groups at an assignment ratio of 1:1:3:2:2:3: placebo, pemafibrate 0.1 mg/day (50 µg bid), pemafibrate 0.2 mg/day (100 µg bid), pemafibrate 0.4 mg/ day (200 µg bid), fenofibrate 100 mg/day (100 mg qd), or fenofibrate 200 mg/day (200 mg qd) (Fig. 1) . This study used micronized fenofibrate capsules. The 100-mg micronized fenofibrate capsule was bioequivalent to an 80-mg fenofibrate tablet. Pemafibrate was administered in tablet form. The double-dummy design was used for blinding of the investigational product: patients in all groups took the same number of preparations with the same appearance using indistinguishable pemafibrate and placebo tablets and indistinguishable fenofibrate and placebo capsules. The drug administration period was 12 weeks with 4-week follow-up period.
Sample Collection and Assessment
Blood and urine were collected for endpoint ana- Patients were randomly assigned to one of six groups (placebo, three doses of pemafibrate, and two doses of fenofibrate).
in the phase study. Under these circumstances, to achieve at least 90% power in the primary analysis, the required number of patients was determined to be 29 in the placebo and pemafibrate 0.1 mg/day groups, 97 in the pemafibrate 0.2 mg/day group, 68 in the pemafibrate 0.4 mg/day group, and 97 in the fenofibrate 200 mg/day group. The target number of patients in the fenofibrate 100 mg/day group was set to the same number as that in the pemafibrate 0.4 mg/ day group to clearly define the effects of pemafibrate. Finally, to accommodate potential discontinuations/ drop-outs and the pre-established allocation ratio (1:1: 3:2:2:3), the following numbers were targeted: 40 in the placebo group, 40 in the pemafibrate 0.1 mg/day group, 120 in the pemafibrate 0.2 mg/day group, 80 in the pemafibrate 0.4 mg/day group, 80 in the fenofibrate 100 mg/day group, and 120 in the fenofibrate 200 mg/day group.
Statistical Analysis
Statistical analysis used a significance level of 5% and a confidence coefficient of 95% on both sides. sis model assessment for insulin resistance (HOMA-R).
The primary safety endpoint was the incidence of AEs and ADRs. Secondary endpoints included (1) the percentages of patients who had aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine kinase (CK), or serum creatinine levels exceeding the cut-off levels ( 3 and 5 ULN for AST and ALT; 2.5 and 5 ULN for CK; 1.5 and 2.0 mg/dL for serum creatinine) or those who had fibrinogen or hemoglobin levels below the cut-off levels (1 , 0.75 , and 0.5 LLN for fibrinogen and 10.0, 8.0, and 6.5 g/dL for hemoglobin) during treatment and (2) changes from week 0 in physiological and clinical test levels (AST, ALT, gamma-glutamyl transpeptidase [ -GT], CK, and serum creatinine levels and (in posthoc analysis) estimated glomerular filtration rate [eGFR]).
Sample Size
The sample size was determined using the results of a previous phase study 20) . To reproduce the previous findings, the study design called for at least 29 patients per group, which is the same number as that For the secondary efficacy endpoints, the levels of the other parameters at the completion of the treatment period were compared to baseline levels. For each group, one-sample t -test was used for determining the change or percent change from baseline and two-sample t -test was used to compare those changes between each pemafibrate group and placebo or each fenofibrate group.
For the analysis of the primary safety endpoints, Fisher's exact test was performed to compare the incidence of AEs and ADRs in each pemafibrate group and placebo or each fenofibrate group and the 95% confidence intervals (CIs) of the differences in incidence were calculated. The dose -response relationship for incidence was examined using the CochranArmitage test.
For the secondary safety endpoints, the percentage of patients whose AST, ALT, CK, or serum creatinine levels exceeded the cut-off value or whose fibrinogen and hemoglobin levels fell below the cut-off value were calculated. The Wilcoxon signed-rank test was performed to assess changes at each time point.
Results
Patients
Patients were enrolled from May 14 to December 27, 2012, in a total of 32 medical institutions in Japan. Informed consent was obtained from 854 paEfficacy analysis set included all patients who were randomized, had at least one dose of the trial drug, and had baseline and post-baseline efficacy measurements. The safety analysis set included all patients who were randomized and had at least one dose of the trial drug.
For primary analysis of the primary efficacy endpoint, the confirmation of a dose -response relationship and assessment of non-inferiority were conducted with the closed testing procedure. To examine the dose -response relationship and superiority over the placebo group, each pemafibrate dose group was compared to the placebo group. In each examination, homogeneity of variance between the placebo and active drug groups was not assumed. The non-inferiority margin was set at 10%. There were four steps in this closed procedure. First, to test whether there was a dose -response relationship using the maximum contrast method, repeated measures analysis of covariance (ANCOVA) was performed on the percent change in fasting serum TG level with baseline as the covariate and weeks 8, 10, and 12 as repeated time points. If those results were significant, the second step was Dunnett's test to compare the three pemafibrate groups with the placebo group. If those results were significant, the third step was to assess the non-inferiority of pemafibrate 0.4 mg/day to fenofibrate 200 mg/day. Fourth, the non-inferiority of pemafibrate 0.2 mg/day was compared with fenofibrate 200 mg/day. Secondary assessments were implemented to test the superiority of pemafibrate 0.2 mg/day and pemafibrate 0.4 mg/day over fenofibrate 200 mg/day and to test the groups. The percent change in TG levels was analyzed using the aforementioned closed procedure. When the dose -response relationship was analyzed in the placebo and pemafibrate dose groups, all contrasts were significant (P 0.001) (Supplementary Table 1 ). The contrast coefficient matrix of ( 5, 1, 3, 3) was selected by the maximum contrast method and confirmed a dose -response relationship. The superiority of all pemafibrate dose groups over the placebo group was also confirmed (Dunnett's test, P 0.001) (Supplementary Table 2 ). The percent change in TG levels ranged from 46% to 52% in pemafibrate groups (Fig. 3) . The change in the pemafibrate 0.4 mg/day group was confirmed to be non-inferior to that in the fenofibrate 200 mg/day group, with the upper limit of the 95% CI of the between-group difference less than 10%, the non-inferiority margin ( 0.3% [95% CI: 5.3%, 4.7%], P 0.906). Similarly, the non-inferiority of pemafibrate 0.2 mg/day to fenofibrate 200 mg/day was confirmed (4.8% [95% CI: 0.4%, 9.3%], P 0.033). No superiority was confirmed in the pemafibrate 0.2 mg/ day or 0.4 mg/day groups compared with the fenofibrate 200 mg/day group. The pemafibrate 0.1, 0.2 and 0.4 mg/day groups were confirmed to be non-inferior and superior ( 8 The results of the secondary efficacy endpoints tients, 526 were randomized to the treatment group, and 489 completed the study (Fig. 2) . Most patients who provided informed consent but were not randomized did not meet the inclusion criteria or satisfied the exclusion criteria based on laboratory test results during the screening period. The drop-out rate was highest in the fenofibrate groups. The trial was discontinued in 0 patients in the placebo group, 3 of 45 (6.7%) patients in the pemafibrate 0. 
Efficacy
For primary endpoint assessment, repeated measures ANCOVA was performed for fasting serum TG levels using baseline as the covariate and weeks 8, 10, and 12 as repetition points. Fasting serum TG levels decreased in all pemafibrate and fenofibrate treatment In repeated measures analysis of covariance (baseline as the covariate and weeks 8, 10, and 12 as repetition points). Data are presented as LS mean (SE).
: P 0.001 vs. baseline. LS, least squares; SE, standard error P value vs. placebo and against fenofibrate 100 mg/day and 200 mg/day were calculated using the 2-sample t -test. Data are presented as mean SD for continuous parameters. Here, n is the number of subjects who had both baseline and post baseline measurements.
: P 0.05, : P 0.01, : P 0.001 vs. baseline (1-sample t -test). : Direct method-Metabo Lead : Ultracentrifugation HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very-low-density lipoprotein cholesterol; RemL-C, remnant lipoprotein cholesterol; Apo, apolipoprotein; HOMA-R, homeostasis model assessment for insulin resistance; SD, standard deviation fenofibrate 200 mg/day group. The incidence of ADRs was 7.0% (3/43) in the placebo group, 4.4% (2/45) in the pemafibrate 0.1 mg/day group, 7.8% (10/128) in the pemafibrate 0.2 mg/day group, 11.8% (10/85) in the pemafibrate 0.4 mg/day group, 14.1% (12/85) in the fenofibrate 100 mg/day group, and 26.4% (37/ 140) in the fenofibrate 200 mg/day group. No dosedependent increase in the incidence of AEs or ADRs was observed among the pemafibrate dose groups (P 0.931 or 0.219, respectively). When compared with the placebo and fenofibrate groups by Fisher's exact test, the incidence of AEs and ADRs in the pemafibrate dose groups showed no marked difference compared with that in the fenofibrate 100 mg/day group, but were significantly less frequent than that in the fenofibrate 200 mg/day group (P 0.05).
There was only one serious AE leading to death in the study: pulmonary embolism in one patient in the pemafibrate 0.4 mg/day group ( Table 3) . This event and all other serious AEs were judged by investigators to have no relationship with the investigational are summarized in Table 2 . HDL-C, apolipoprotein A-(ApoA-), ApoA-, and LDL-C levels increased and VLDL-C, RemL-C, ApoB48, ApoC-, ApoC-, and ApoC-/ApoC-levels decreased in all pemafibrate and fenofibrate groups. Non-HDL-C levels decreased in all groups other than the pemafibrate 0.4 mg/ day group, and TC, ApoB, and ApoB100 levels decreased in the fenofibrate 200 mg/day group. Fasting plasma glucose levels decreased in the pemafibrate 0.4 mg/day and fenofibrate 200 mg/day groups, fasting insulin levels decreased in the pemafibrate 0.2 and 0.4 mg/day groups, and HOMA-R decreased in the pemafibrate 0.2 mg/day group.
Safety
The incidence of AEs ( sis-/myopathy-related AEs was low and similar to placebo in all pemafibrate and fenofibrate dose groups ( Table 4 ). The incidence of nasopharyngitis was ≥ 5% in some pemafibrate dose groups, but the incidence did not markedly differ from the incidence in the placebo group.
In the analysis of liver function test results, AST, ALT, and -GT levels markedly increased in the fenofibrate groups compared with those in the placebo and pemafibrate groups. ALT and -GT levels significantly decreased in the pemafibrate dose groups from baseline to weeks 4 to 12 (Fig. 4) .
In kidney function tests, serum creatinine and eGFR levels dramatically increased and decreased, respectively, in the fenofibrate groups, particularly in the 200 mg/day group, compared with those in the placebo and pemafibrate groups (Fig. 4) . CK levels were nearly unchanged. Table 5 shows the number of patients with laboratory test results exceeding the cut-off values or going below the cut-off values. Four patients (4.7%) in the fenofibrate 100 mg/day group and seven (5.0%) in the fenofibrate 200 mg/day group had ALT levels that rose to 3 ULN. No patients in the placebo or pemafibrate groups had ALT levels this high. Results were similar for AST levels. CK level changes exceeded 2.5 or 5 ULN in some patients in the pemafibrate groups, but the percentage of patients with such changes product. No serious ADRs were observed. AEs that led to the discontinuation of the study drug occurred in 4.4% (2/45) of the patients in the pemafibrate 0.1 mg/day group, 1.6% (2/128) of the patients in the 0.2 mg/day group, 1.2% (1/85) of the patients in the 0.4 mg/day group, 3.5% (3/85) of the patients in the fenofibrate 100 mg/day group, and 10.0% (14/140) The incidence of liver-related AEs was 8.2% (7/85) in the pemafibrate 0.4 mg/day dose group, but this incidence was similar to that in the placebo group (9.3%). In contrast, 13 of 85 (15.3%) patients treated with fenofibrate 100 mg/day and 34 of 140 (24.3%) patients treated with fenofibrate 200 mg/day had liverrelated AEs ( Table 4) . The incidence of rhabdomyoly- : P 0.05, : P 0.01, : P 0.001 vs. baseline (Wilcoxon signed-rank test). AST, aspartate aminotransferase; ALT, alanine aminotransferase; -GT, gamma-glutamyl transpeptidase; CK, creatine kinase; eGFR, estimated glomerular filtration rate fenofibrate capsules with 134 mg/day) 19) . In an earlier phase study, TG reductions were at least 10% greater in pemafibrate-treated patients (0.2 mg/day or 0.4 mg/day) than in fenofibrate patients (100 mg/ day), but the difference was not significant 20) . The statistical significance in the current study was likely due to the higher patient numbers and greater statistical power.
Similar trends were observed in the present study for other TG-related indicators, including VLDL-C, RemL-C, and ApoC-. At all doses, pemafibrate provided more potent improvement in TG-rich lipoprotein levels than fenofibrate 100 mg/day, and the effects of pemafibrate 0.2 mg/day and 0.4 mg/day were equivalent to those of fenofibrate 200 mg/day. Pemafibrate groups tended to show decreased fasting serum glucose levels and decreased fasting insulin levels. Treatment with pemafibrate may thus help reduce insulin resistance. This point requires further investigation.
In the present study, LDL-C levels increased in the pemafibrate and fenofibrate groups. Many enrolled patients had hyperlipidemia Type , which is often associated with increases in LDL-C levels after treatment with fenofibrate or bezafibrate. With fenofibrate, LDL-C levels may increase, even when these levels are initially low 23) . In patients with high TG levels but low LDL-C levels, VLDLs account for a relatively high proportion of apoB-containing lipoproteins, and LDL-C was similar to that in the placebo group. The serum creatinine level exceeded 2.0 mg/dL in 1 patient in the pemafibrate 0.2 mg/day group. This increase was considered to be an AE (increased blood creatinine level) but was judged to be "not related" to the trial drug.
Discussion
In this multicenter, randomized study, pemafibrate treatment demonstrated potent and dose-dependent reduction in TG levels at 0.1, 0.2 and 0.4 mg/ day in patients with high TG and low HDL-C levels. This is the first study to compare the safety and efficacy of pemafibrate with the maximum dose of fenofibrate (200 mg/day). Pemafibrate 0.2 mg/day and 0.4 mg/day were confirmed to be non-inferior to fenofibrate 200 mg/day, and pemafibrate 0.1 to 0.4 mg/day was confirmed to be superior to fenofibrate 100 mg/ day for reducing TG levels. The incidence of AEs/ ADRs in all pemafibrate groups was confirmed to be comparable to that of placebo and less frequent than that of fenofibrate 200 mg/day. Overall, pemafibrate 0.4 mg/day was superior to fenofibrate 200 mg/day.
The efficacy results in the current study were consistent with another phase study that found that pemafibrate 0.2 mg/day and 0.4 mg/day provided significantly better reduction in TG levels than fenofibrate tablets (106.6 mg/day, equivalent to micronized Drug effectiveness in real-world clinical practice is clearly affected by the number of treatment discontinuations due to AEs. To maximize the effectiveness of a drug, it is necessary to minimize treatment discontinuations. In the present study, the discontinuation rate was 10% for fenofibrate 200 mg/day (14 of 140 patients). The primary reason was concern for patient safety following worsening of liver function (11 patients). The pemafibrate groups showed one treatment discontinuation due to ALT level elevation in the 0.2 mg/day group and no discontinuations due to worsening liver function in the 0.4 mg/day (high dose) group. The low level of discontinuation suggests that patients can benefit from the highly potent reduction in TG levels at a high dose without compromising safety. Additionally, the ACCORD study prespecified rules for discontinuation or dose reduction based on laboratory values, including eGFR 11) . A comparison of fenofibrate and placebo in the same study found greater eGFR reduction (2.4% vs. 1.1%) and a higher rate of dose reduction with fenofibrate 11) . These results suggest that some patients are unable to benefit from the maximum fenofibrate dose. In contrast, pemafibrate appears to cause very little reduction in eGFR, even at the maximum dose. For this reason, we can anticipate few instances of drug withdrawal. These favorable efficacy and safety results compared to fenofibrate may also be related to findings that pemafibrate qualifies as a SPPARM , which permits the separation of desirable effects from adverse effects 16, 17) . This study has some limitations. First, the treatment period was short (12 weeks), and the sample size was moderate. Correlating the present findings to clinical outcomes, such as the prevention of cardiovascular events or acute pancreatitis, will require a larger study conducted over a longer duration. The ongoing PROMINENT study (NCT03071692), expected to have about four years of follow-up, should provide additional data on these kinds of clinical events 3) . Particularly, the risk of pulmonary embolism was slightly higher in the fenofibrate group than in the placebo group in the FIELD study 28) . Pulmonary embolism may be of interest in clinical practice, although it was not observed in the ACCORD study, and the instance observed in the pemafibrate 0.4 mg/day group was reported to have no relationship with pemafibrate by the investigator 11) . Second, in comparison with other clinical studies of pemafibrate, the upper limit of baseline TG levels in the present study was high (1000 mg/dL). Therefore, it may be possible that various baseline patient characteristics were not sufficiently homogenized by randomization, which may have made it difficult to interpret the results. Third, patients receiving concomitant statin therapy or those with levels may increase as a result of TG-rich lipoprotein catabolism enhanced by treatment with those agents. Often, in clinical practice, LDL-C levels are initially elevated after fibrate treatment but then gradually decrease with continued fibrate treatment in combination with diet therapy. In the study mentioned above 23) , LDL-C levels increased after fenofibrate treatment compared to placebo, but the difference in LDL-C levels between the groups gradually diminished during the 104-week treatment period. No further details are available, but there might be integrated effects on slightly different baseline characteristics of patients, such as mean baseline levels and/or distribution of TG and LDL-C levels.
In addition to demonstrating efficacy, this study also confirmed the safety of pemafibrate. The incidence of AEs and ADRs in all pemafibrate groups was similar to that in the placebo group and less frequent than that in the fenofibrate groups; these differences between each of the pemafibrate groups and the fenofibrate 200 mg/day group were significant. More specifically, pemafibrate was associated with a low risk of AEs related to liver function. Even at the highest dose (0.4 mg/day) in the present study, pemafibrate was associated with reduced ALT and -GT levels. In contrast, fenofibrate, particularly at a high dose (200 mg/day), caused further elevation in ALT and -GT levels. These observations are consistent with previous preclinical and clinical findings 19, 20, [24] [25] [26] . Unlike fenofibrate, pemafibrate is primarily excreted into the bile 27) . In rats, pemafibrate provided more potent reduction in TG levels than fenofibrate with less increase in liver weight 18) . In another double-blind comparative study, liver-related AEs occurred in 6.8% of patients in the pemafibrate 0.2 mg/day group, 0% of those in the pemafibrate 0.4 mg/day group, and 39.5% of those in the fenofibrate 106.6 mg/day group 19) . The ability of pemafibrate to potently reduce TG levels without affecting liver function clearly distinguishes it from fenofibrate.
The present study also confirmed the safety profile of pemafibrate related to renal function over fenofibrate. The greatest reduction in eGFR was noted at the maximum dose of fenofibrate (200 mg/day), which was even more extensive than that for fenofibrate 100 mg/day; eGFR was minimally affected by the maximum dose of pemafibrate (0.4 mg/day). In another phase study, fenofibrate was associated with increases in serum creatinine levels and decreases in eGFR, but these changes were minimal in the pemafibrate group 19) . In the same study, the incidence of kidneyrelated AEs was 0% in the pemafibrate 0.2 mg/day and 0.4 mg/day groups and 3.9% in the fenofibrate 106.6 mg/day group 19) .
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Conclusion
In patients with high TG and low HDL-C levels, pemafibrate treatment at 0.1, 0.2, and 0.4 mg/day demonstrated potent and dose-dependent reduction in TG levels in comparison with placebo and fenofibrate at 100 and 200 mg/day; the results also suggested a favorable benefit -risk balance compared with fenofibrate. The favorable safety profile of pemafibrate, including fewer adverse effects on kidney/liverrelated laboratory tests and fewer AEs/ADRs, including those leading to treatment discontinuation, may provide a broader range of patients with this novel and potent treatment option for reducing TG levels. 
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